-C Ferran Researcher Activity Profile

Research Author Detailed Information 

C Ferran Publication Rate By Year

C Ferran has published 1 paper(s) in 1996, 1 paper(s) in 1997, 1 paper(s) in 1998, 2 paper(s) in 1999, 3 paper(s) in 2002, 2 paper(s) in 2003, 1 paper(s) in 2004, 2 paper(s) in 2005, 2 paper(s) in 2006, 2 paper(s) in 2007, for a total of 17 research publications in total.

C C Ferran Author Information

LAST NAME: ferran

FIRST NAME: C

INITIALS: c

AFFILIATION:

Papers

C Ferran's Publication Record

1. The universal NF-kappaB inhibitor a20 protects from transplant vasculopathy by differentially affecting apoptosis in endothelial and smooth muscle cells. Year Published: 2006
Departments of Surgery and Medicine, Beth Israel Deaconess Medical Centre Harvard Medical School, Boston, Massachusetts 022152, USA.
2. A novel function for cadherin 11/osteoblast-cadherin in vascular smooth muscle cells: modulation of cell migration and proliferation. Year Published: 2007
Department of Surgery, Division of Vascular Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
3. Comparison of gene silencing in human vascular cells using small interfering RNAs. Year Published: 2007
Department of Surgery, Division of Vascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
4. A20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. Year Published: 2002
Department of Surgery and Medicine, Immunobiology Research Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA.
5. Expression of protective genes in human renal allografts: a regulatory response to injury associated with graft rejection. Year Published: 2002
Division of Immunology, Department of Medicine, Immunobiology Research Center, Harvard Medical School, Boston, MA 02215, USA.
6. The graft unveils its secrets: provocative therapeutic leads to protected vascularized allografts. Year Published: 2002
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. cferran@caregroup.harvard.edu
7. Genetic engineering of a suboptimal islet graft with A20 preserves beta cell mass and function. Year Published: 2003
Immunobiology Research Center, Department of Surgery and Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. sgrey@caregroup.harvard.edu
8. A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis. Year Published: 2003
Immunobiology Research Center, Department of Surgery and Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass 02215, USA.
9. A20 protects endothelial cells from TNF-, Fas-, and NK-mediated cell death by inhibiting caspase 8 activation. Year Published: 2004
Department of Surgery and Medicine, 99 Brookline Ave, Boston MA 02215, USA.
10. A20 blocks endothelial cell activation through a NF-kappaB-dependent mechanism. Year Published: 1996
Sandoz Center for Immunobiology, Deaconess Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
11. Adenovirus-mediated gene transfer of A20 renders endothelial cells resistant to activation: a means of evaluating the role of endothelial cell activation in xenograft rejection. Year Published: 1997
Sandoz Center for Immunobiology, Deaconess Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
12. Adenovirus-mediated expression of a dominant negative mutant of p65/RelA inhibits proinflammatory gene expression in endothelial cells without sensitizing to apoptosis. Year Published: 1998
Immunobiology Research Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
13. A novel function for A20 in smooth muscle cells: inhibition of activation and proliferation. Year Published: 1999
Immunobiology Research Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
14. A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets. Year Published: 1999
Immunobiology Research Center, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA. sgrey@caregroup.harvard.edu
15. Functional dichotomy of A20 in apoptotic and necrotic cell death. Year Published: 2005
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. pstorz@bidmc.harvard.edu
16. Combined expression of A1 and A20 achieves optimal protection of renal proximal tubular epithelial cells. Year Published: 2005
Division of Vascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
17. A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia. Year Published: 2006
The Immunobiology Research Center, Harvard Medical School, Boston Massachusetts, USA.